Logo image of DRRX

DURECT CORPORATION (DRRX) Stock Fundamental Analysis

NASDAQ:DRRX - Nasdaq - US2666055007 - Common Stock - Currency: USD

0.6  +0.03 (+4.35%)

Premarket: 0.629 +0.03 (+4.83%)

Fundamental Rating

3

Overall DRRX gets a fundamental rating of 3 out of 10. We evaluated DRRX against 195 industry peers in the Pharmaceuticals industry. DRRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DRRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DRRX has reported negative net income.
DRRX had a negative operating cash flow in the past year.
In the past 5 years DRRX always reported negative net income.
DRRX had a negative operating cash flow in each of the past 5 years.
DRRX Yearly Net Income VS EBIT VS OCF VS FCFDRRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.21%, DRRX is in line with its industry, outperforming 48.72% of the companies in the same industry.
With a Return On Equity value of -91.81%, DRRX perfoms like the industry average, outperforming 42.05% of the companies in the same industry.
Industry RankSector Rank
ROA -34.21%
ROE -91.81%
ROIC N/A
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
DRRX Yearly ROA, ROE, ROICDRRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

DRRX has a better Gross Margin (40.32%) than 61.03% of its industry peers.
DRRX's Gross Margin has been stable in the last couple of years.
DRRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 40.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
DRRX Yearly Profit, Operating, Gross MarginsDRRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

DRRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DRRX has more shares outstanding
The number of shares outstanding for DRRX has been increased compared to 5 years ago.
There is no outstanding debt for DRRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DRRX Yearly Shares OutstandingDRRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DRRX Yearly Total Debt VS Total AssetsDRRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -60.91, we must say that DRRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -60.91, DRRX is not doing good in the industry: 92.82% of the companies in the same industry are doing better.
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -60.91
ROIC/WACCN/A
WACC12.5%
DRRX Yearly LT Debt VS Equity VS FCFDRRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

DRRX has a Current Ratio of 1.23. This is a normal value and indicates that DRRX is financially healthy and should not expect problems in meeting its short term obligations.
DRRX has a worse Current ratio (1.23) than 78.46% of its industry peers.
DRRX has a Quick Ratio of 1.22. This is a normal value and indicates that DRRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.22, DRRX is doing worse than 69.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.22
DRRX Yearly Current Assets VS Current LiabilitesDRRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

DRRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.52%, which is quite impressive.
The Revenue for DRRX has decreased by -41.75% in the past year. This is quite bad
DRRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -39.51% yearly.
EPS 1Y (TTM)83.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
Revenue 1Y (TTM)-41.75%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-82.43%

3.2 Future

Based on estimates for the next years, DRRX will show a very strong growth in Earnings Per Share. The EPS will grow by 60.95% on average per year.
The Revenue is expected to grow by 53.91% on average over the next years. This is a very strong growth
EPS Next Y-116.59%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue Next Year-94.87%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DRRX Yearly Revenue VS EstimatesDRRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
DRRX Yearly EPS VS EstimatesDRRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRRX Price Earnings VS Forward Price EarningsDRRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRRX Per share dataDRRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

DRRX's earnings are expected to grow with 57.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.45%
EPS Next 3Y57.26%

More info and screens

0

5. Dividend

5.1 Amount

DRRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DURECT CORPORATION

NASDAQ:DRRX (6/11/2025, 8:00:01 PM)

Premarket: 0.629 +0.03 (+4.83%)

0.6

+0.03 (+4.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-05 2025-08-05
Inst Owners22.18%
Inst Owner Change0.89%
Ins Owners10.78%
Ins Owner Change0%
Market Cap18.62M
Analysts82.22
Price Target5.1 (750%)
Short Float %2.9%
Short Ratio6.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)751.12%
Min EPS beat(2)-9.24%
Max EPS beat(2)1511.48%
EPS beat(4)3
Avg EPS beat(4)388.46%
Min EPS beat(4)-9.24%
Max EPS beat(4)1511.48%
EPS beat(8)6
Avg EPS beat(8)212.44%
EPS beat(12)9
Avg EPS beat(12)143.92%
EPS beat(16)13
Avg EPS beat(16)112.24%
Revenue beat(2)1
Avg Revenue beat(2)-37.45%
Min Revenue beat(2)-82.8%
Max Revenue beat(2)7.9%
Revenue beat(4)1
Avg Revenue beat(4)-23.47%
Min Revenue beat(4)-82.8%
Max Revenue beat(4)7.9%
Revenue beat(8)2
Avg Revenue beat(8)-22.97%
Revenue beat(12)2
Avg Revenue beat(12)-23.09%
Revenue beat(16)4
Avg Revenue beat(16)-5.19%
PT rev (1m)-25.93%
PT rev (3m)-25.93%
EPS NQ rev (1m)-5.41%
EPS NQ rev (3m)0%
EPS NY rev (1m)-3.61%
EPS NY rev (3m)-10.26%
Revenue NQ rev (1m)-8.15%
Revenue NQ rev (3m)-78.8%
Revenue NY rev (1m)-13.43%
Revenue NY rev (3m)-81.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.84
P/FCF N/A
P/OCF N/A
P/B 3.48
P/tB 7.09
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.16
BVpS0.17
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.21%
ROE -91.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 40.32%
FCFM N/A
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.22
Altman-Z -60.91
F-Score4
WACC12.5%
ROIC/WACCN/A
Cap/Depr(3y)86.47%
Cap/Depr(5y)78.99%
Cap/Sales(3y)0.86%
Cap/Sales(5y)0.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
EPS Next Y-116.59%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue 1Y (TTM)-41.75%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-82.43%
Revenue Next Year-94.87%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%
EBIT growth 1Y45.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.08%
OCF growth 3YN/A
OCF growth 5YN/A